GlassScriptPhysician profile
David Anthony Florez
NPI 1003805011
$13,532.23
in general payments reported to CMS, 2019-2025
39 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,145 · 2020: $861 · 2021: $1,841 · 2022: $2,104 · 2023: $2,550 · 2024: $2,299 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,565 · Education: $16.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,564.56 |
| Education | $16.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,174.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,766.74 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,262.65 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $1,128.73 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $565.86 | 2019-2025 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $478.38 | 2020-2023 | |
| Ardelyx, INC. | $472.00 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $353.48 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $337.81 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $290.13 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $262.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $249.15 | 2019-2025 | |
| Daiichi Sankyo INC. | $243.03 | 2019-2024 | Injectafer |
| Celltrion USA INC. | $190.10 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $178.41 | 2024-2025 | Zenpep |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $177.85 | 2021-2025 | Interstim |
| Intercept Pharmaceuticals, INC. | $176.48 | 2019-2025 | Ocaliva |
| Celgene Corporation | $174.58 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $167.50 | 2019-2024 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $158.14 | 2022-2025 | Dupixent |
| Genzyme Corporation | $115.30 | 2022-2024 | |
| Organon LLC | $106.61 | 2023-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $69.71 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $64.16 | 2019-2025 | Sutab, Suflave |
| Neuraxis, INC. | $58.37 | 2025 | |
| Novo Nordisk INC | $44.04 | 2025 | Wegovy |
| Allergan, INC. | $36.23 | 2019-2020 | |
| Enterra Medical, INC. | $35.83 | 2022-2023 | |
| Redhill Biopharma INC. | $30.73 | 2020-2022 | |
| Gilead Sciences, INC. | $27.18 | 2019 | |
| Ethicon US, LLC | $21.26 | 2022 | |
| Boston Scientific Corporation | $20.12 | 2025 | Cre Pro |
| Azurity Pharmaceuticals, INC. | $18.65 | 2025 | Sutab |
| Alfasigma USA, INC. | $17.36 | 2020 | |
| Capsovision, INC. | $16.08 | 2024 | Capsocam Plus |
| Shionogi INC | $13.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.80 | 2019 | |
| Horizon Therapeutics Plc | $11.67 | 2021 | |
| Romark Laboratories, Lc | $5.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Florez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.